The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

Cullinan Oncology, Taiho Pharmaceuticals complete agreement to develop and commercialize CLN-081/TAS6417

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Cullinan Oncology Inc. and Taiho Pharmaceutical Co. Ltd. completed their agreement to collaborate on the U.S. development of CLN-081/TAS6417, a next generation, irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with non-small cell lung cancer (The Cancer Letter, May 13, 2022). 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Nuvalent announces positive topline pivotal data from ALKOVE-1 trial of neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC

Nuvalent, a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced positive topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in tyrosine kinase inhibitor pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 phase I/II clinical trial. 
Drugs & Targets

FDA approves Hyrnuo for HER2-mutated NSCLC

FDA has approved Hyrnuo (sevabertinib), an oral, reversible, tyrosine kinase inhibitor, for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
Drugs & Targets

Cue Biopharma and ImmunoScape collaborate to develop cell therapy approach for solid tumors

Cue Biopharma, a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, and ImmunoScape, a biotechnology company developing next-generation T cell receptor-based therapies in oncology, announced that they have entered into a collaboration and license agreement to advance a novel in vivo approach to cell therapy for the treatment of solid tumors. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account